Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Recommendations on screening for breastcancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breastcancer in women aged 40–74 years who are not at increased risk for breastcancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breastcancer in women aged 40–74 years who are not at increased risk for breastcancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breastcancer with mammography results in a modest reduction in breastcancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives
Should This Woman With Dense Breasts Receive Supplemental BreastCancerScreening?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Breastcancer will develop in 12% of women during their lifetime and is the second leading cause of cancer death among U.S. women. Mammography is the most commonly used tool to screen for breastcancer. Considerable uncertainty exists regarding the age at which to begin screening and the optimal screening interval. Breast density is a risk factor (...) for breastcancer. In addition, for women with dense breasts, small tumors may be missed on mammography and the sensitivity of screening is diminished. At the time of publication, 35 states had passed laws mandating that breast density be reported in the letters that radiologists send to women with their mammogram results. The mandated language may be challenging for patients to understand, and such reporting may increase worry for women who are told that their risk for breastcancer is higher than
Knowledge, Beliefs, and Attitudes About BreastCancerScreening in Latin America and the Caribbean: An In-Depth Narrative Review Purpose Breastcancer (BCA) is the most common cancer and leading cause of cancer mortality among women in Latin America and the Caribbean (LAC), and the number of deaths from BCA is expected to continue to increase. Although barriers to care include the physical accessibility of screening resources, personal and cultural barriers must be explored to understand (...) to identify articles. Thirty-five articles were included according to inclusion and exclusion criteria. Results Themes identified in the literature included knowledge about screening procedures and cause of cancer; knowledge sources; catalysts and deterrents for screening, such as family support, family history; social support or taboo, fear, self-neglect, cost, and transportation; and the perception of the screening experience. Conclusion In addition to physical availability of resources and health care
Breastcancerscreening Top results for breastcancerscreening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might (...) look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for breastcancerscreening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical
The Association of Health Literacy with BreastCancer Knowledge, Perception and Screening Behavior The incidence of breastcancer among Iranian women is increasing, and 70% of patients are diagnosed at advanced stages. The current study aimed at evaluating the association of health literacy (HL) with breastcancer knowledge, perception, and screening behavior in women.The current cross- sectional, descriptive study was conducted on 250 women who referred to health centers in Zahedan, Iran. Data (...) ), and with perceived susceptibility.Interventions to enhance breastcancer knowledge and screening should notice the HL of women.
Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers. In 30 states, women who have had screening mammography are informed of their breast density on the basis of Breast Imaging Reporting and Data System (BI-RADS) density categories estimated subjectively by radiologists. Variation in these clinical categories across and within radiologists has led to discussion about whether automated BI-RADS density should (...) be reported instead.To determine whether breastcancer risk and detection are similar for automated and clinical BI-RADS density measures.Case-control.San Francisco Mammography Registry and Mayo Clinic.1609 women with screen-detected cancer, 351 women with interval invasive cancer, and 4409 matched control participants.Automated and clinical BI-RADS density assessed on digital mammography at 2 time points from September 2006 to October 2014, interval and screen-detected breastcancer risk, and mammography
A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breastcancer metastasis Tumor cells disseminate early in tumor development making metastasis-prevention strategies difficult. Identifying proteins that promote the outgrowth of disseminated tumor cells may provide opportunities for novel therapeutic strategies. Despite multiple studies demonstrating that the mesenchymal-to-epithelial transition (MET) is critical for metastatic colonization, key regulators (...) that initiate this transition remain unknown. We serially passaged lung metastases from a primary triple negative breastcancer xenograft to the mammary fat pads of recipient mice to enrich for gene expression changes that drive metastasis. An unbiased transcriptomic signature of potential metastatic drivers was generated, and a high throughput gain-of-function screen was performed in vivo to validate candidates. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) was identified
The overestimation and the inappropriate promotion of the benefits of mammographic screening in breastcancer research and interventions in the Gaza Strip. There has been extensive debate about whether mammographic screening has done more good than harm. Recent reviews showed that women who undergo mammographic screening are more likely to have a tumour that was an overdiagnosis and therefore would not cause them problems. In the Gaza Strip, a strong forum of people advocate an increase (...) women have low survival rates because of the poor availability of mammography. Only three study groups mentioned harmful effects of mammographic screening. All educational materials had clear information on the benefits of mammographic screening but minimal information on its harms.Research in the Gaza Strip overestimated the reduction in breastcancer mortality that can be attributable to mammographic screening, and this would encourage women to undergo screening without knowing that it could harm
Association of Screening and Treatment With BreastCancer Mortality by Molecular Subtype in US Women, 2000-2012. Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breastcancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden.To evaluate the contributions associated with screening and treatment to breastcancer mortality reductions by molecular subtype based (...) , overall, and ER/ERBB2-specific breastcancer mortality rates from 2000 to 2012 for women aged 30 to 79 years relative to the estimated mortality rate in the absence of screening and treatment (baseline rate); mortality reductions were apportioned to screening and treatment.In 2000, the estimated reduction in overall breastcancer mortality rate was 37% (model range, 27%-42%) relative to the estimated baseline rate in 2000 of 64 deaths (model range, 56-73) per 100 000 women: 44% (model range, 35%-60
BreastCancerScreening Behaviors of First Degree Relatives of Women Receiving BreastCancer Treatment and the Affecting Factors First-degree relatives of women with breastcancer are under higher risk when compared with the general population. The aim of this study is to evaluate breastcancerscreening behaviors of women who are first-degree relatives of women with breastcancer and factors affecting these behaviors.This descriptive study included 240 patient relatives, who agreed (...) to participate in the study through contact with first-degree relatives of 133 patients who were receiving breastcancer treatment at the Oncology and Chemotherapy unit of an university hospital in Turkey. Data were collected using the "Descriptive Characteristics Form," which consisted of socio-demographic characteristics, health history, breastcancer risk level and health beliefs as well as the "BreastCancerScreening Behavior Evaluation Form".Out of the subjects, 17% reported doing breast self
â€œThanks for Letting Us All Share Your Mammogram Experience Virtuallyâ€: Developing a Web-Based Hub for BreastCancerScreening The decision around whether to attend breastcancerscreening can often involve making sense of confusing and contradictory information on its risks and benefits. The Word of Mouth Mammogram e-Network (WoMMeN) project was established to create a Web-based resource to support decision making regarding breastcancerscreening. This paper presents data from our user (...) to explore the advantages and limitations of this approach. The second objective was to analyze what women want from a Web-based resource for breastcancer screening.We recruited a user design group on Facebook and conducted a survey within the group, asking questions about design considerations for a Web-based breastcancerscreening hub. Although the membership of the Facebook group varied over time, there were 71 members in the Facebook group at the end point of analysis. We next conducted a framework
The WISDOM Study: breaking the deadlock in the breastcancerscreening debate There are few medical issues that have generated as much controversy as screening for breastcancer. In science, controversy often stimulates innovation; however, the intensely divisive debate over mammographic screening has had the opposite effect and has stifled progress. The same two questions-whether it is better to screen annually or bi-annually, and whether women are best served by beginning screening at 40 (...) or some later age-have been debated for 20 years, based on data generated three to four decades ago. The controversy has continued largely because our current approach to screening assumes all women have the same risk for the same type of breastcancer. In fact, we now know that cancers vary tremendously in terms of timing of onset, rate of growth, and probability of metastasis. In an era of personalized medicine, we have the opportunity to investigate tailored screening based on a woman's specific
Evaluation on the Practice and Behaviour of Women Applied for Gynecology Outpatient Clinics About Screening Methods for Early Diagnosis of BreastCancerBreast self-examination (BSE), clinical breast exam (CBE), mammography and ultrasound imaging (UI) are screening methods used for early diagnosis of breastcancer (BC). The purpose of this study is to put forth the utilization frequency of these screening methods among women presenting to the gynecology outpatient clinics and the relation (...) mammography and CBE are at less-than-ideal levels. In this context, it is apparent that breastcancerscreening methods are needed to be introduced and guidance about their application frequency should be provided for women in gynecology outpatient clinics.
Cost-Effectiveness of BreastCancerScreening in Turkey, a Developing Country: Results from BahÃ§eÅŸehir Mammography Screening Project We used the results from the first three screening rounds of Bahcesehir Mammography Screening Project (BMSP), a 10-year (2009-2019) and the first organized population-based screening program implemented in a county of Istanbul, Turkey, to assess the potential cost-effectiveness of a population-based mammography screening program in Turkey.Two screening (...) strategies were compared: BMSP (includes three biennial screens for women between 40-69) and Turkish National BreastCancer Registry Program (TNBCRP) which includes no organized population-based screening. Costs were estimated using direct data from the BMSP project and the reimbursement rates of Turkish Social Security Administration. The life-years saved by BMSP were estimated using the stage distribution observed with BMSP and TNBCRP.A total of 67 women (out of 7234 screened women) were diagnosed
BreastCancerScreening in Women at Above Average Risk Oregon Health Authority : Health Evidence Review Commission : Health Evidence Review Commission : State of Oregon menu Toggle Main Menu Main Navigation close search Search search Submit You are here: Health Evidence Review Commission menu Site Navigation Health Evidence Review Commission Full Width Column 1 Health Evidence: Our Role The Health Evidence Review Commission reviews medical evidence in order to prioritize health spending
The epidemiology, radiology and biological characteristics of interval breastcancers in population mammography screening An interval breastcancer is a cancer that emerges following a negative mammographic screen. This overview describes the epidemiology, and the radiological and biological characteristics of interval breastcancers in population mammography screening. Notwithstanding possible differences in ascertainment of interval breastcancers, there was broad variability in reported (...) interval breastcancer rates (range 7.0 to 49.3 per 10,000 screens) reflecting heterogeneity in underlying breastcancer rates, screening rounds (initial or repeat screens), and the length and phase of the inter-screening interval. The majority of studies (based on biennial screening) reported interval breastcancer rates in the range of 8.4 to 21.1 per 10,000 screens spanning the two-year interval with the larger proportion occurring in the second year. Despite methodological limitations inherent
Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening in Women at Less Than High Risk for BreastCancer Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening in Women at Less Than High Risk for BreastCancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening (...) in Women at Less Than High Risk for BreastCancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screeningbreast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breastcancer and who have no personal history of breastcancerBreastcancer is the most common cancer among Canadian women. The most common form of screening for breastcancer
Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes PreventionandscreeninginBRCAmutationcarriersand otherbreast/ovarianhereditarycancersyndromes: ESMOClinicalPracticeGuidelinesforcancerprevention andscreening † S.Paluch-Shimon 1 ,F.Cardoso 2 ,C.Sessa 3 ,J.Balmana 4 ,M.J.Cardoso 2 ,F.Gilbert 5 &E.Senkus 6 , onbehalfoftheESMOGuidelinesCommittee * 1 DivisionofOncologyandtheDrPinchasBorensteinTalpiotMedicalLeadershipProgram,ShebaMedicalCenter (...) - tions and databases to optimise recommendations and care for screening,preventionandfollow-upinthispopulation. prevalenceandepidemiology Hereditary cancer syndromes arise from a germline mutation, inherited from either parent, resulting in a signi?cantlyelevated risk of cancer development relative to that of the general populationthatdoesnotharbouramutationinacancersuscep- tibility gene. Speci?cally, a germline mutation in BRCA1 or BRCA2resultsinasigni?cantlyelevatedlifetimeriskofdevelop- ing breast
[Invitation and decision guide for breastcancerscreening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breastcancerscreening] Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0 [Invitation and decision guide for breastcancerscreening] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Einladungsschreiben und entscheidungshilfe zum mammographie-screening: abschlussbericht; auftrag P14-0. [Invitation and decision guide for breastcancerscreening] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG